These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26504398)

  • 1. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Calabrese C; Terracciano R; Lombardo N; Maselli R
    Ther Clin Risk Manag; 2015; 11():1563-72. PubMed ID: 26504398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
    Cataldo D
    Rev Med Liege; 2016 Jun; 71(6):308-313. PubMed ID: 28383865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
    Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
    Calzetta L; Matera MG; Cazzola M; Rogliani P
    Adv Ther; 2019 Dec; 36(12):3291-3298. PubMed ID: 31654332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol.
    Criner G; Duffy S
    Curr Med Res Opin; 2021 Feb; 37(2):275-284. PubMed ID: 33095662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
    Maltais F; de la Hoz A; Casaburi R; O'Donnell D
    Adv Ther; 2021 Feb; 38(2):835-853. PubMed ID: 33306188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium.
    Pelaia G; Maselli R; Gallelli L
    Multidiscip Respir Med; 2014; 9(1):64. PubMed ID: 25699181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D; Mahler DA; Hanania NA
    Expert Rev Respir Med; 2016 Jul; 10(7):767-80. PubMed ID: 27223863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
    Koblížek V; Svoboda M
    Vnitr Lek; 2016; 62(12):1011-1020. PubMed ID: 28139131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
    Montuschi P; Ciabattoni G
    J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies of dual bronchodilation in COPD.
    Cazzola M; Matera MG; Rogliani P; Calzetta L
    Monaldi Arch Chest Dis; 2021 Feb; 91(1):. PubMed ID: 33586398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.
    Calzetta L; Rogliani P; Matera MG; Cazzola M
    Chest; 2016 May; 149(5):1181-96. PubMed ID: 26923629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olodaterol + tiotropium bromide for the treatment of COPD.
    Calzetta L; Ciaprini C; Puxeddu E; Cazzola M
    Expert Rev Respir Med; 2016 Apr; 10(4):379-386. PubMed ID: 26894830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
    Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.
    Calzetta L; Rogliani P; Page C; Rinaldi B; Cazzola M; Matera MG
    Pulm Pharmacol Ther; 2019 Jun; 56():39-50. PubMed ID: 30876907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.